Keel Point’s Kalaris Therapeutics KLRS Stock Holding History

Keel Point’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,225	Closed	-$86.3K	–	580
2025 Q4	$86.3K	Buy	+10,225	New	+$65.4K	0.01%	529

Other funds holding KLRS

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Alyeska Investment Group

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Kalehua Capital Management Dallas, Texas $141M AUM

Raymond James Financial

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Keel Point's KLRS Position: Q1 2026 in Review

Keel Point sold out of Kalaris Therapeutics (KLRS) in Q1 2026, closing a stake of 10,225 shares — an estimated $86.3K sold.

Keel Point first reported a position in KLRS in Q4 2025 and held it in 1 quarter. The position peaked at $86.3K in Q4 2025. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

Keel Point reported no remaining Kalaris Therapeutics position as of Q1 2026 after selling out during the quarter.
Keel Point sold 10,225 Kalaris Therapeutics shares in Q1 2026, an estimated $86.3K.
Keel Point first reported a position in Kalaris Therapeutics in Q4 2025 and held it in 1 quarter.
Keel Point's Kalaris Therapeutics position peaked at $86.3K in Q4 2025.
58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Keel Point's 13F filing for Q1 2026, filed 1 Jun 2026.